Contact Us

These non-promotional scientific presentations were presented at the medical congresses referenced below and are intended for U.S healthcare professionals who were in attendance for the purposes of scientific exchange.

These materials may contain information outside of the FDA approved label or relate to uses that have not been approved by the FDA. Syndax does not recommend use of Syndax products in any manner other than as described in the FDA-approved Prescribing Information.

Italian Society of Hematology

Rome, Italy Sep 21 - 23, 2026

Results 3

Oral Presentation | Sep 21, 2026

C014: Revumenib + intensive chemotherapy for newly diagnosed acute myeloid leukemia harboring genetic alterations in KMT2A, NPM1, or NUP98: updated Phase 1 results from SNDX-5613-0708

Papayannidis C, et al.

View Material

Poster Presentation | Sep 21, 2026

P088: A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed NPM1-mutated OR KMT2A-rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2 / HO177 / AMLSG35-24 / ACT-HOV-AML-002): Trial in progress

Venditti A, et al.

View Material

Poster Presentation | Sep 21, 2026

P200: A phase 3 study of revumenib in combination with intensive chemotherapy in patients with newly diagnosed npm1-mutated acute myeloid leukemia (REVEAL-ND NPM1): trial in progress

Cairoli R, et al.

View Material